Sept. 30 marked 61 days since July 31, one day past the timeframe President Donald Trump had set forth for companies to lower ...

EMA's draft reflection paper promotes using patient experience data in drug regulation to enhance decision-making processes.

In this continuation of a three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

FDA's Center for Biologics Evaluation and Research has released updated draft recommendations for sponsors of cell therapies, gene therapies, and tissue products.

The 100% tariff on imported drugs will pressure pharma companies to build manufacturing sites in the US or face significant ...

Alvin Jogasuria, ProBio; Matthew Lunning, University of Nebraska Medical Center; and Carl Schoellhammer, DeciBio, go behind ...

The FDA draft guidance "Considerations for Complying with 21 CFR 211.110" raises points to consider regarding drug products ...

David McErlane, Group President of Biologics at Catalent, shares how integrated expertise in biologics helps simplify ...

In this episode of the Ask the Expert video series, Susan J. Schniepp, Regulatory Compliance Associates, and Siegfried Schmitt, PhD, Parexel, answer questions on the use of real-world evidence for ...

Saleem Farooqui of Fresenius Kabi explains how the company is addressing today’s pharmaceutical manufacturing needs. Watch this video to learn how these capabilities can help bring products to market ...

Pharmaceutical Technology® spoke with Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK, to learn more about Crown Bioscience’s collaboration with Medicines ...

Your weekly news hub for biopharma trends, FDA regulations, M&A deals, supply chain insights, drug development innovations from BIO-Europe, and more.